11 Bilder zum Thema "pd 1" bei ClipDealer

Medien sortieren nach     Gehe zu Seite:    
« Vorherige  1  Nächste »
Immune checkpoint inhibitors in cancer treatment, 3D illustration. Inhibitors of PD-1 receptor and PD-L1 prevent the tumour cell from binding to PD-1 and enable the T cell to remain active
Cancer cells express PD-L1 (orange) proteins on their surface to trick the immune system. The interaction of PD-L1 with PD-1 of T-cells leads to a down-regulation of T-cells. The antibody (yellow) blocks this interaction.
Molecular model of Pembrolizumab, a humanized antibody used in immunotherapy of cancer, 3D illustration. It targets the PD-1 receptor of lymphocytes
PD-1 (red) extends from the surface of a T-cell and interacts with the ligand protein PD-L1 (yellow) from a antigen presenting cell. Although the T-cell has been activated through the interaction of a T-cell receptor (blue) and a MHC protein (viole
Molecular model of Pembrolizumab, a humanized antibody used in immunotherapy of cancer, 3D illustration. It targets the PD-1 receptor of lymphocytes
Immune checkpoint inhibitors in cancer treatment, 3D illustration. Inhibitors of PD-1 receptor and PD-L1 prevent the tumour cell from binding to PD-1 and enable the T cell to remain active
Molecular model of Pembrolizumab, a humanized antibody used in immunotherapy of cancer, 3D illustration. It targets the PD-1 receptor of lymphocytes
Immunologically active proteins on a T-cell. TCR (blue), CD-4 (light blue), CD-28 (dark blue), PD-1 (magenta), CTLA-4 (violet), Ca-channel (dark violet). The T-cell receptor, CD-4 and CD-28 activate T-cells, while PD-1 and CTLA-4 inhibit the activat
Interactions of MHC-II with the T-cell receptor and CD4 and B7-1 with CD-28 activates T-cells while the interactions of P7-1 with CTLA-4 and PD-L1 with PD-1 deactivates T-cells.
Interaction of MHC-II (red) with the T-cell receptor (blue) and CD4 (light blue) and B7-1 (orange) with CD-28 (dark blue) activates T-cells while the interaction of P7-1 with CTLA-4 (violett) and PD-L1 (yellow) with PD-1 deactivates T-cells
Molecular model of Pembrolizumab, a humanized antibody used in immunotherapy of cancer, 3D illustration. It targets the PD-1 receptor of lymphocytes

« Vorherige  1  Nächste »